Bain Capital Selling Stake in Emcure Pharma

Bain Capital-affiliated entity BC Investments IV is reportedly set to offload a 2.4% stake in Emcure Pharmaceuticals via a block deal, valued at ₹551 crore. The transaction, priced at ₹1,279.80 per share—slightly below the previous close—is expected to be managed by Kotak Securities . As of March 2025, BC Investments IV held an 8.68% stake in Emcure, making this partial exit a significant development for the pharma stock. The move comes as the company reported a 63% YoY rise in net profit and 19.5% growth in revenue during Q4 FY25. Despite strong financials, Emcure’s stock has underperformed recently, falling nearly 13% YTD from its September 2024 high of ₹1,580. However, it remains 27% above its IPO price of ₹1,008, set when the company listed in July 2024. The stake sale could influence short-term trading sentiment but reflects confidence in the company’s long-term prospects.